Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
:PYPD
Earnings Data
Report Date
Feb 11, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.33Last Year’s EPS
-1.13Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call for PolyPid Ltd.'s third quarter of 2025 highlighted significant progress towards regulatory approval and commercial readiness for DPLEX 100, with strong validation from market studies and reduced financial losses. However, increased administrative and marketing expenses posed challenges. Overall, the positive aspects considerably outweigh the negatives.Company Guidance
Successful Pre-NDA and European Readiness
PolyPid Ltd. is on track with its pre-NDA meeting scheduled for early December with the FDA and plans to submit the NDA for DPLEX 100 in early 2026, leveraging Fast Track and Breakthrough Therapy designations. The company is also preparing for the submission of the European Marketing Authorization Application following the NDA.
Positive Phase III Trial Results
The SHIELD II trial demonstrated a 58% reduction in surgical site infections with DPLEX 100, resulting in strong interest from surgeons and pharmacy directors and indicating significant commercial potential.
Financial Performance Improvements
PolyPid Ltd. reported a reduced net loss of $7.5 million for the quarter, compared to $7.8 million in the prior year, and increased cash reserves to $18.8 million, up from $15.6 million at year-end 2024.
Market Access Study Validation
A new US market study confirmed strong interest in DPLEX 100 from surgeons and hospital pharmacy directors, with 80% of surgeons likely to use it for eligible patients and 70% of pharmacy directors likely to add it to the formulary.
PYPD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PYPD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $3.76 | $3.75 | -0.27% |
Aug 13, 2025 | $3.42 | $3.49 | +2.05% |
May 14, 2025 | $2.71 | $2.90 | +7.01% |
Feb 12, 2025 | $2.88 | $2.97 | +3.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does PolyPid Ltd. (PYPD) report earnings?
PolyPid Ltd. (PYPD) is schdueled to report earning on Feb 11, 2026, Before Open (Confirmed).
What is PolyPid Ltd. (PYPD) earnings time?
PolyPid Ltd. (PYPD) earnings time is at Feb 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PYPD EPS forecast?
PYPD EPS forecast for the fiscal quarter 2025 (Q4) is -0.33.